维普中文期刊产品整合服务
199篇 您的检索式:作者名="Vose JM"
    题名 作者 年代 出处 被引量
1Autologous transplantation for diffuse aggressive non- Hodgkin s lymphoma in patients never achieving remission:a report from the autologous blood and marrow transplant registry 显示文摘 Zhang MJ Rowlings PA 2001J Clin Oncol2001,19,2:1
2Cytokine use in the old patient 显示文摘Vose JM 1995Semin Oncol1995,22,1:1
3Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international pe- ripheral T-cell lymphoma project 显示文摘Delabie J Holte H Vose JM 2011Blood2011,118,1:1
4ALK - anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project 显示文摘Savage KJ Harris NL Vose JM 2008Blood2008,111,15:1
5An international phase II trial of single - agent lenalidomide for relapsed or refractory aggressive B - cell non - Hodgkin's lympho- ma显示文摘Witzig TE Vose JM Zinzani PL 2011Ann Oncol2011,,:1
6Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma显示文摘 Gordon BG Vose JM 1996Blood1996,87,9:1
7Mantle cell lymphoma: 2015 update on diagnosis risk - stratification and clinical management 显示文摘Vose JM 2015Am J Hematol2015,90,8:1
8Mantle cell lymphoma:2013 Update on diagnosis,risk-stratification,and clinical management显示文摘Vose JM 2013Am J Hematol2013,88,12:1
9Phase Ⅰ/Ⅱ trial of multiple dose ^131I odine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma 显示文摘Vose JM Coleher D Gobar L 2000Leuk Lymphoma2000,3,:1
10Phase Ⅱ study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin' s lymphoma 显示文摘Vose JM Link BK Grossbard ML 2001J Clin Oncol2001,19,2:1
11International Peripheral T-cell Lymphoma(PTCL)Clinical and Pathologic Review Project:poor outcome by prognostic indices and lack of efficacy with anthracyclines显示文摘Vose JM 2005Blood2005,1006,11:1
12Bexxar: Novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma显示文摘Vose JM 2004Oncologist2004,9,2:1
13Phase Ⅱ study of enzastaurin,a protein kinase C beta inhibitor,in patients with relapsed or refractory diffuse large B-cell lymphoma显示文摘Robertson MJ Kahl BS Vose JM 0,,13:1
14A phase II study of the survivin suppressant YM155in patients with refractory diffuse large B-cell lymphoma显示文摘Cheson BD Bartlett NL Vose JM 2012Cancer2012,118,:1
15Phase Ⅲ randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine- 131 tositumomab /BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B - cell lymphoma: Results from the BMT CTN 0401 trial 显示文摘Vose JM Carter S Burns LJ 2013J Clin Oncol2013,31,13:1
16Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease显示文摘Albitar M Vose JM Johnson MM 0,,02:1
17ALK-negative anaplastic large-cell lymphoma (ALCL) is clinically and immunophenotypically different from both ALK-positive ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project 显示文摘Savage KJ Harris NL Vose JM 2008Blood2008,111,12:1
18Phase Ⅱ study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma 显示文摘Robertson M J Kahl BS Vose JM 2007J Clin Oncol2007,25,13:1
19Advances in mobilization for the optimization of autologous stem cell transplantation显示文摘Vose JM Ho AD Coiffier B 2009Leuk Lymphoma2009,50,9:1
20ALK^- anaplasfic large-cell lympboma is clinically and immunophenotypieally different from both ALK ^+ ALCL and peripheral T-cell lymphoma,not otherwise specified:report from the International Peripheral T-Cell Lymphoma Project 显示文摘Savage K J Harris NL Vose JM 2008Blood2008,111,12:1
返回顶部 每页显示:
共10页 首页 上一页 第1页 下一页 末页 /10 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费